UK MHRA Device Register: 22,554 Devices, UK Manufacturing Base & Post-Brexit Registration

Executive Summary

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) maintains a public register of medical devices approved for the UK market. Our analysis of the complete MHRA dataset — 22,554 registered device records from 4,445 unique manufacturers across 75 countries — reveals a market with a substantial domestic manufacturing base, a dominant IVD segment, and a registration landscape in transition as the UK completes its post-Brexit regulatory divergence.

Key findings: UK-based manufacturers hold 33.5% of all registered devices (7,548 of 22,554), a significantly higher domestic share than comparable registers in Taiwan (25.9%) or Brazil (27.9%). The United States is the second-largest source at 23.5% (5,310 devices), followed by Germany at 13.8% (3,103 devices). In-vitro diagnostics (IVD) account for 37.7% of all registrations, and the top 10 manufacturers hold 13.1% of registrations (HHI of 31).

The UK is at a regulatory inflection point. The draft Medical Devices (Amendment) Regulations 2026, laid before Parliament on 8 May 2026, are expected to be adopted by December 2026 and come into force by June 2027. These regulations introduce international reliance pathways — allowing the MHRA to recognise approvals from the US FDA, Australia TGA, and Health Canada — and set a definitive end to the CE marking transition period. UKCA marking becomes compulsory after June 2030 for all device classes.

This article breaks down the MHRA register by device type, manufacturing geography, manufacturer concentration, and registration status — providing regulatory strategists and market-access teams with a quantitative foundation for UK market planning during a period of significant regulatory change.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the MHRA Devices and Manufacturers public datasets (extracted March 2026). The devices dataset contains 22,554 records with fields including: device ID, GMDN code and term name, device sub-type description, device type name, device registration status code, and last updated date. The manufacturers dataset contains 12,685 records with fields including: manufacturer organisation ID, organisation name, country, and current status indicator.

Device type classification follows MHRA's categories: General Medical Device, In Vitro Diagnostic (IVD), System/Procedure Pack, and Active Implantable. Manufacturer country was taken directly from the country field, with UK sub-regions (England, Scotland, Wales, Northern Ireland) aggregated into a single "United Kingdom" count. Where a manufacturer appears under multiple organisation IDs, device counts were aggregated by organisation name. Registration status codes: DREGIY indicates active registration, CACEXP indicates expired/cancelled.

Concentration metrics were computed using standard Herfindahl-Hirschman Index (HHI) methodology. Percentages are calculated against the total relevant denominator (all 22,554 device records unless otherwise noted).

The UK Regulatory Landscape: Post-Brexit Transition

The UK medical device market is estimated at USD 19–28 billion (2025–2032 projections, 5.6% CAGR), making it one of the largest in Europe. Since Brexit, the MHRA has been building an independent regulatory framework while managing the transition from CE marking (under EU directives) to UKCA marking.

The Regulatory Timeline

International Reliance Pathways

The 2026 Amendment Regulations introduce reliance pathways that will allow the MHRA to recognise device approvals from specified international regulators. From 2027, devices with prior approval from the US FDA (510(k), De Novo, or PMA pathways), Australia TGA, or Health Canada may qualify for expedited UK registration. This represents a significant departure from the EU framework's emphasis on mutual recognition exclusively within the European Economic Area.

The MHRA-FDA collaboration, formalised in October 2025 and strengthened in April 2026, goes beyond reliance to include joint scientific advice, parallel review pilots, and shared post-market surveillance intelligence.

Device Type Distribution

The 22,554 registered devices break down by MHRA device type classification as follows:

The IVD share of 37.7% is notably high — significantly above the typical 15–25% range seen in most national device registers. This reflects the UK's substantial domestic IVD manufacturing base (Siemens Healthcare Diagnostics Products Limited, Leica Biosystems, Biorex Diagnostics, and others) and the country's role as a European hub for clinical laboratory diagnostics.

Active Implantable devices, at just 0.9%, represent the smallest but most clinically significant category — encompassing cardiac pacemakers, implantable defibrillators, and neurostimulators.

Manufacturing Geography: A Strong Domestic Base

Among 22,554 registered devices, manufacturers are located in 75 countries. The distribution shows a substantially higher domestic manufacturing share than most comparable markets:

UK sub-regions included: England (6,183 devices), Northern Ireland (618), Wales (395), Scotland (352).

Three observations stand out:

1. Domestic manufacturing is strong. At 33.5%, the UK's domestic device share is higher than Taiwan (25.9%), Brazil (27.9%), and Singapore (where domestic manufacturing is minimal). This reflects the UK's established medical device industry, particularly in IVD and diagnostic imaging.

2. US manufacturers are the dominant foreign source. At 23.5%, US-headquartered manufacturers supply nearly a quarter of all UK-registered devices — reflecting the deep integration of US and UK medical device markets and the shared language, regulatory culture, and clinical practice patterns.

3. European concentration. The UK, Germany, Switzerland, France, Italy, and Ireland collectively account for 56.5% of all registrations, underscoring the continued importance of European manufacturing supply chains despite Brexit.

Top Manufacturers: Siemens Leads

The top 20 manufacturers account for 19.6% of all registrations, with Siemens Healthcare Diagnostics holding the largest share:

Note: Siemens Healthcare Diagnostics Inc. (750 devices) and Siemens Healthcare Diagnostics Products Ltd (293 devices) appear as separate entities but are part of the same corporate family. Combined, Siemens accounts for 1,043 devices (4.6% of all registrations).

Concentration metrics:

• Top 5 manufacturers: 1,851 devices (8.2%)
• Top 10 manufacturers: 2,953 devices (13.1%)
• Top 20 manufacturers: 4,418 devices (19.6%)
• HHI: 31 (low concentration)

The HHI of 31 indicates a highly fragmented market with no single manufacturer dominating. The average manufacturer holds just 5 registrations. IVD manufacturers (Siemens, Roche, EUROIMMUN, Biorex, Leica Biosystems) feature prominently, consistent with the 37.7% IVD share of the overall register.

Registration Status

The vast majority of registrations (94.0%) remain active. The relatively low expired/cancelled rate may reflect the ongoing CE-to-UKCA transition period — devices with valid CE marking continue to be recognised on the UK market, reducing the incentive for manufacturers to withdraw registrations.

As the June 2030 deadline approaches — when UKCA marking becomes compulsory — a wave of registration updates and renewals is expected, particularly for EU-based manufacturers who may need to establish UK Responsible Person (UKRP) arrangements and submit new UKCA marking applications.

The UK in Context: Regulatory Crossroads

The UK medical device market is at a unique regulatory crossroads in 2026:

1. International reliance signals openness. The introduction of reliance pathways from FDA, TGA, and Health Canada is a significant departure from EU practice. For manufacturers with prior US or Australian approvals, the UK could become a faster market-access route than the EU — particularly given the well-documented bottlenecks in EU Notified Body capacity under the MDR.

2. UKRP requirements create barriers. Non-UK manufacturers must appoint a UK Responsible Person (UKRP) to register devices with the MHRA. The UKRP is responsible for regulatory correspondence and post-market vigilance. For non-UK manufacturers, the choice of UKRP is a long-term commercial relationship that cannot be changed without regulatory process.

3. DORS is now mandatory. The Defect Offence Reporting System (DORS) and the associated Device Registration Service are now mandatory for all device manufacturers placing products on the UK market. This digital registration system replaces the previous paper-based process.

4. Clinical investigation landscape. The MHRA's evolving approach to clinical investigations for medical devices — including recognition of foreign clinical data — may make the UK an attractive jurisdiction for clinical evidence generation, particularly for companies seeking parallel regulatory pathways with the US.

5. Post-Brexit market dynamics. While the UK remains a major market, some EU-based manufacturers face increased costs and complexity in maintaining UK market access. Conversely, US manufacturers with established FDA approvals may find the new reliance pathways reduce the incremental cost of UK registration.

Implications for Market Entry

The data and regulatory context suggest several actionable insights:

• US manufacturers with FDA approvals are well-positioned. The upcoming reliance pathways will reduce the time and cost of UK registration for devices already cleared or approved by the FDA. The 23.5% US share of the current register is likely to grow as reliance pathways take effect.

• IVD manufacturers face specific considerations. With 37.7% of the register, IVD devices are a dominant segment. The UK's strong domestic IVD manufacturing base means foreign IVD manufacturers face established domestic competition.

• The 2030 deadline is approaching. Manufacturers currently relying on CE marking to access the UK market must plan for UKCA compliance. The June 2028 deadline (end of MDD/AIMDD recognition) and June 2030 deadline (end of MDR/IVDR recognition) create a clear planning horizon.

• UKRP selection is strategic. The UKRP relationship is long-term and not easily transferable. Manufacturers should evaluate UKRP options based on regulatory competence, geographic coverage, and post-market vigilance capabilities.

Key Takeaways

• 22,554 registered devices across General Medical Device (58.6%), IVD (37.7%), System/Procedure Pack (2.8%), and Active Implantable (0.9%)
• UK manufacturers hold 33.5% of all registrations — a strong domestic base compared to Taiwan (25.9%) or Brazil (27.9%)
• US manufacturers hold 23.5%; the UK, US, and Germany together account for 70.8%
• 4,445 unique manufacturers with an HHI of 31 — a highly fragmented, competitive landscape
• Siemens Healthcare Diagnostics leads with 750 devices (combined entities: 1,043, 4.6%)
• IVD accounts for 37.7% of registrations, a notably high share reflecting the UK's diagnostic manufacturing base
• 94.0% of registrations remain active — the CE-to-UKCA transition has not yet triggered mass withdrawals
• Regulatory change is imminent — the Amendment Regulations 2026 introduce international reliance pathways and set the UKCA transition end-date

Data Source

Analysis sample: MHRA Devices and Manufacturers public datasets (extracted March 2026), 22,554 device records and 12,685 manufacturer records. Device type from DEVICE_TYPE_NAME field. Manufacturer country from MAN_COUNTRY field, with UK sub-regions (England, Northern Ireland, Scotland, Wales) aggregated. Concentration metrics computed via HHI. All numbers reflect the public register and may differ slightly from MHRA's internal records due to timing of data publication.